ReachRxResearch
Home
Research
Sign Up
Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis
Back to Research Hub
  1. Home
  2. Research Hub
  3. Atacicept in IgA Nephropathy — Phase 3 T…

Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis

New England Journal of Medicine·October 22
Medicine, General & InternalPractice changingIgA NephropathyRandomized Controlled TrialBAFF/APRIL InhibitorAdultAtacicept

Summary

View source

What was studied

Weekly subcutaneous atacicept 150 mg vs. placebo in 428 adults with biopsy-confirmed IgA nephropathy (214 per group) over 104 weeks (ORIGIN 3 phase 3 RCT), evaluating eGFR change at week 52, annualized eGFR slope through week 104, composite kidney-disease progression, and safety.

Key findings

At week 52, mean eGFR change was -0.11 vs. -5.69 mL/min/1.73 m² (difference +5.58; P<0.001). Through week 104, annualized eGFR slope was -0.60 vs. -5.60 mL/min/1.73 m²/year (difference +5.00; P<0.001). Composite kidney-disease progression occurred in 5.1% (atacicept) vs. 17.8% (placebo) — hazard ratio 0.24 (95% CI 0.12–0.48; P<0.001); 0 vs. 7 patients progressed to dialysis, transplantation, or death.

Study limitations

Trial duration was 2 years, so very long-term kidney outcomes (beyond week 104) remain unknown. The trial enrolled adults only, limiting generalizability to pediatric IgA nephropathy. Background standard-of-care therapies were not uniformly described in the abstract, making it harder to isolate atacicept's effect in real-world practice.

Clinical implications

Atacicept 150 mg weekly SC nearly halted eGFR decline over 2 years and cut kidney-disease progression events by ~76% vs. placebo — clinicians managing IgA nephropathy patients at risk of progression should consider this as a potential disease-modifying option. Serious adverse events were lower with atacicept (7.0%) than placebo (15.4%), suggesting a favorable safety profile.

Caveats

  • Composite kidney-disease progression was a secondary endpoint; the trial's primary endpoint (urinary protein-to-creatinine ratio reduction) was reported in a prior publication, so this paper represents final but not first efficacy reporting
  • Funded by Vera Therapeutics (manufacturer of atacicept), introducing potential industry sponsorship bias
  • Placebo group showed an unexpectedly rapid eGFR decline (-5.69 mL/min/1.73 m² at 52 weeks), which may reflect a higher-risk population and limit generalizability to all IgA nephropathy patients

Related Questions

Explore related topics

What other BAFF/APRIL inhibitors are being studied for IgA nephropathy?How does atacicept compare to sparsentan or budesonide in slowing eGFR decline in IgA nephropathy?What are the long-term safety considerations of BAFF/APRIL dual blockade in kidney disease?

Publication Details

Year
2026
Journal
New England Journal of Medicine
Sample Size
n=428
Source
View article
Keep scrolling
More content below.
Up Next